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Allogeneic hematopoietic cell transplantation (alloHCT) with reduced-intensity conditioning is an appealing
option for patients with high-risk multiple myeloma (MM). However, progression after alloHCT remains a
challenge. Maintenance therapy after alloHCT may offer additional disease control and allow time for a graft-
versus-myeloma effect. The primary objective of this clinical trial was to determine the tolerability and safety
proﬁle of maintenance lenalidomide (LEN) given on days 1 to 21 of 28 days cycles, with intrapatient dose
escalation during 12 months/cycles after alloHCT. Thirty alloHCT recipients (median age, 54 years) with high-
risk MM were enrolled at 8 centers between 2009 and 2012. The median time from alloHCT to LEN initiation
was 96 days (range, 66 to 171 days). Eleven patients (37%) completed maintenance and 10 mg daily was the
most commonly delivered dose (44%). Most common reasons for discontinuation were acute graft-versus-
host disease (GVHD) (37%) and disease progression (37%). Cumulative incidence of grades III to IV acute
GVHD from time of initiation of LEN was 17%. Outcomes at 18 months after initiation of maintenance were
MM progression, 28%; transplantation-related mortality, 11%; and progression-free and overall survival, 63%
and 78%, respectively. The use of LEN after alloHCT is feasible at lower doses, although it is associated with a
38% incidence of acute GVHD. Survival outcomes observed in this high-risk MM population warrant further
study of this approach.
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14.04.014INTRODUCTION
Multiple myeloma (MM) is a heterogeneous and incurable
hematologic malignancy characterized by the preferential
proliferation of clonal plasma cells in the bone marrow [1-3].
Outcomes after therapy, especially progression-free survival
(PFS) and overall survival (OS), vary depending on the bio-
logic characteristics present at diagnosis, including elevated
b2- microglobulin, and cytogenetic abnormalities involvingTransplantation.
Table 1
Baseline Patient Characteristics
Characteristics Value
No. of patients 30
Age, median (range), yr 54 (38-68)
Male/female 14/16 (47/53)
Disease status before LEN maintenance
CR/VGPR/PR 15/6/9 (50,20,30)
High-risk MM Categories
Relapse after autologous HCT 6 (20)
Beta2 microglobulin  5.5 mg/L 6 (20)
Plasmablastic morphology > 2% 5 (17)
Chromosome 13 deletion 13 (43)
t(4;14) 6 (20)
Hypodiploidy 2 (7)
17p deletion 2 (7)
t(14;16) 1 (3)
Median prior lines of therapy 1.76
Prior lenalidomide therapy 13 (43)
Unrelated/related donor 12/18
Conditioning regimens
Fludarabine and melphalan ( 140 mg/m2) 12 (40)
TBIþ ﬂudarabine  cyclophosphamide 8 (27)
TBI ( 500 cGY single/ 800 fractionated) 8 (27)
TBI ( 900 cGY fractionate) þ melphalan
( 100 mg/m2)
2 (7)
Time from diagnosis to AlloHCT, median
(range), mo
10 (3-188)
Time from AlloHCT to maintenance, median
(range), d
96 (66-171)
Follow-up, median (range), mo 21 (3-35)
CR indicates complete response; VGPR, very good partial response, PR,
partial response, LEN, lenalidomide; MM, multiple myeloma; HCT, he-
matopoietic cell transplantation; TBI, total body irradiation; Allo HCT,
allogeneic HCT.
Data presented are n (%), unless otherwise indicated.
M. Alsina et al. / Biol Blood Marrow Transplant 20 (2014) 1183e11891184chromosome 13 [4,5], chromosome 14 [6,7], deletion p53,
hypodiploidy [8], high-risk gene expression proﬁle, and
plasmablastic morphology [9]. Patients with any of these
features are considered to have high-risk MM and multiple
studies have invariably shown signiﬁcantly decreased PFS
and OS, even in the setting of single or tandem autologous
transplantation. Despite major therapeutic advances ach-
ieved in this disease, the management of patients with high-
risk MM remains a challenge and an unmet need [10-12].
Current practices incorporate bortezomib-based regimens
in these patients, followed by autologous transplantation
(autoHCT). However, this approach fails to induce durable
responses in the majority of these patients [13-15].
Although the role of alloHCT in MM remains controver-
sial, several studies have shown encouraging PFS and OS
with this treatment modality with prolonged follow-up and
even in patients with high-risk disease [16,17]. In contrast to
initial studies using alloHCT in MM with treatment-related
mortality in the range of 40% to 50%, recent studies using
nonmyeloablative and reduced-intensity conditioning regi-
mens have shown transplantation-related mortality (TRM)
rates of around 10% to 15%, with the main cause of treatment
failure and mortality being disease progression [17-19].
Therefore, when considering this treatment approach inMM,
post-transplantation treatment strategies need to be devel-
oped to prevent disease progression.
Lenalidomide (LEN) is an immunomodulatory drug (IMiD)
with established efﬁcacy in MM [20,21]. Although the exact
anti-MM mechanism of action of LEN is unknown, a number
of mechanisms are postulated to be responsible for its ac-
tivity against MM, including its effect on angiogenesis, T cell
proliferation, and increased cytokine production, which can
lead to enhanced natural killer cell activity [22].
In the autoHCT setting, the use of LEN maintenance after
transplantation was associated with prolonged PFS in 2
randomized trials and improvement in OS in 1 trial, estab-
lishing an important role for LEN as maintenance therapy
[23,24].
In this study, we evaluate the tolerability, feasibility, and
safety of LEN maintenance therapy after alloHCT for patients
with high-risk MM.
MATERIALS AND METHODS
Patient Population
Eligible patients were 18 to 70 years of age, with chemosensitive, high-
risk MM, who had received an alloHCT from an 8/8 or 7/8 HLA allele match
(at A, B, C, DRB1) related or unrelated donor within 60 to 180 days of study
enrollment. High-risk MM was deﬁned by the presence of at least 1 of the
following characteristics: deletion of chromosome 13, hypodiploidy, t(4;14),
t(14;16) deletion 17p, plasmablastic morphology, elevated b2-microgolbulin
(>5.5 mg/dL), or relapse after autoHCT. Patients were required to have a
Karnofsky performance score  80 or Eastern Cooperative Oncology Group
score 2. Patients received a reduced-intensity conditioning regimen based
upon the Center for International Blood and Marrow Transplant Research
(CIBMTR) deﬁnition for the alloHCT [25], and graft-versus-host disease
(GVHD) prophylaxis consisted of a calcineurin inhibitor in combinationwith
either methotrexate, mycophenolate mofetil, or sirolimus. Patients were
required to have 2 separate donor recipient chimerism assessments (pe-
ripheral blood or bone marrow) before study entry. The most recent
assessment needed to be  14 days before initiation of LEN. Chimerism
results needed to be at least 50% donor with no evidence of falling donor
chimerism when assessing both measurements.
Patients were excluded if they had active grade III to IV GVHD, absolute
neutrophil count< 1500 cells/mm3, hemoglobin level< 8.0 g/dL (transfusion
support and/orerythropoietinwasallowed), platelet count<75,000 cell/mm3
(transfusion support not allowed within the 7 days before enrollment),
creatinine clearance < 50 mL/minute, total bilirubin >2 mg/dL, serum
transaminases> 3 the upper limit of normal, or had received> 3 prior lines
of therapy. Lines of therapywere deﬁned as sequential therapies separated by
disease progression events.This clinical trial was conducted in accordance with the Declaration of
Helsinki and the International Conference of Harmonization for Good
Clinical Practice. The study was approved by the institutional review boards
of all participating institutions and by the National Marrow Donor Program
institutional review board. All study participants provided voluntarywritten
informed consent.
Study Design
This was a multi-institutional, nonrandomized, open label, Phase IIa
prospective trial to evaluate the safety, feasibility, and tolerability of main-
tenance LEN after alloHCT (CIBMTR Resource for Clinical Investigation in
Blood and Marrow Transplantation Protocol 07-Rev, clinicaltrials.gov;
NCT00847639). The primary objective of the study was to determine the
tolerability and safety proﬁle of a maximum of 12 cycles or 12 months from
ﬁrst dose (whichever came ﬁrst) of LEN after alloHCT for high-risk MM.
Secondary objectives were to estimate the incidences of grade III to IV
adverse events, graft failure, infections, TRM, incidence and severity of acute
and chronic GVHD, best response rates, and time to disease progression and
OS after LEN initiation. Patients were followed from initiation of LEN
maintenance therapy to 30 days after completion of 12 cycles of therapy or
12 months from ﬁrst dose of study drug (whichever came ﬁrst) or discon-
tinuation of therapy.
All patients could receive supportive therapies during study participa-
tion as per institutional guidelines, including granulocyte colonyestimulat-
ing factors, erythropoietin, antiemetics, antimicrobials, analgesics, packed
red blood cells, and platelet transfusions. Prophylactic anticoagulation
therapy was administered at the discretion of the treating physician using
aspirin, warfarin, or low-molecular-weight heparin. Treatment of GVHDwas
according to institutional guidelines.
Dose Escalation
Patients were treated with LEN starting within 60 to 180 days after
alloHCT given on days 1 to 21 of 28 days cycles. Dose escalation and de-
escalation were performed depending on tolerability to LEN. The starting
dose of LEN for all patients was 10 mg/day.
If no toxicity occurred after a 28-day cycle, the dose of LEN was
increased by 5 mg increments on day 1 of the subsequent cycle until the
maximum dose of 25 mg/day was reached. If the patient experienced a
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reduced to 1 level lower (or 5 mg) and maintained at this level for all sub-
sequent cycles, unless further toxicities occurred. The lowest dose allowed
in study was 5 mg every other day. Dose re-escalation was not permitted.
LEN was discontinued in the event of disease progression, graft failure,
development of grade III to IV GVHD, inability to start planned cycle within
56 days of intended start date, or an adverse event judged by the investi-
gator to necessitate discontinuation of the drug.
All study participants were required to register for the mandatory
RevAssist program and be willing and able to comply with the requirements
of RevAssist. Toxicity evaluation was done weekly for cycles 1 to 4 and
monthly for the remainder of the cycles.
Assessments
Adverse events were graded using the Common Terminology Criteria for
Adverse Events version 3.0 and were reported to the local institutional re-
view boards and CIBMTR. Patients were evaluable for safety assessment if
they received at least 1 dose of study treatment. Patients were assessed for
treatment response based on International Myeloma Working Group uni-
form criteria [26].
The Resource for Clinical Investigation in Blood and Marrow Trans-
plantation Data Safety Monitoring Board reviewed a summary of all adverse
events and prespeciﬁed stopping rule outcomes twice per year.
Statistical Analysis
The primary analysis was descriptive in nature. First, we estimated, with
95% conﬁdence intervals, the proportion of evaluable patients who
completed 12 cycles or 12 months of LEN maintenance. Patients who were
not evaluable or who failed the primary endpoint were described and the
reasons described and summarized. Doses per cycle, maximum doses, and
most tolerated doses were described. For patients not in complete response
(CR) at study initiation, the frequencies and proportions of patientsLenalidomide, Cycle 1
N=30 (100%), Doses1:
10mg(n=30)
Lenalidomide, Cycle 3
N=21 (70%), Doses:
5mg QOD (n=3), 5 mg QD (n=4), 10mg 
(n=11), 15mg (n=2), 20mg (n=1)
Lenalidomide, Cycle 6
N=19 (63%), Doses:
5mg QOD (n=6), 5 mg QD (n=4), 
10mg (n=7), 25mg (n=2)
Lenalidomide, Cycle 12
N=12 (40%), Doses:
5mg QOD (n=2), 5 mg QD (n=1),
10mg (n=2), 20mg (n=2), 25mg (n=1),
Held2 (n=4)
Lenalidomide, Cycle 9
N=16 (53%), Doses:
5mg QOD (n=7), 5 mg QD (n=2), 
10mg (n=3), 15mg (n=2), 20mg (n=1)
Completed Lenalidomide
N=11 (37%)
Figure 1. Flow diagram of all treated patients (n ¼ 30). *Lenalidomide dose at the
completed 12 months of maintenance before 12 cycles. GVHD, graft-versus-host diseresponded were described. For patients in CR at study initiation, the fre-
quencies and proportion of patients who maintained their CR were
described. Patients who died after progression were considered as a treat-
ment failure or no response. Patients who died from TRM were considered
not evaluable for response. The distribution of the best response since
initiation of LEN was described using frequencies and percentages. Out-
comes of disease progression or relapse, grade II to IV and III to IV acute
GVHD (aGVHD) were calculated from time of initiation of LEN maintenance
and calculated using cumulative incidence function to account for com-
peting risks. Outcomes of PFS and OS were calculated using the Kaplan-
Meier method, starting at time of initiation of LEN. Additionally,
incidences of grade 3 or higher toxicities, infections, graft failure, and
chronic GVHD were described.
There were prespeciﬁed stopping rules for the following 3 outcomes:
TRM, graft failure, and grade III to IV aGVHD; events of these types were
actively followed by the external data safety monitoring board. There were
no episodes of graft failure after initiation of LEN and the rates of TRM and
aGVHD (both< 20% within 113 days from exposure to LEN) were lower than
the speciﬁed boundaries for stopping.
RESULTS
Patient Characteristics
Thirty patients were enrolled in this study from April
2009 to January 2012 from 8 study centers in the United
States. Baseline patient and disease characteristics are listed
in Table 1.
The median age was 54 years (range, 38 to 68) and the
median time from diagnosis to alloHCT was 10 months
(range, 3 to 188). One patient received a graft from a 7/8 HLA-
matched donor, and the remainder of patients received 8/8Off Therapy, n=4
PD (n=3 ),  Infection (n=1)
Off Therapy, n=3
PD (N=1), Patient refusal 
(n=1), Neutropenia (n=1)
Off Therapy, n=2
Neutropenia (n=1), PD (n=1)
Off Therapy, n=9
GVHD (n=7), PD (n=1), Skin 
rash (N=1)
Off Therapy, n=1
PD (n=1 )
start of the cycle. yPatients who held lenalidomide doses during cycles and
ase; QD, daily; QOD, every other day; PD, progressive disease.
Table 2
Disease Status, Myeloma Response and Graft-Versus-Host Disease by Patient
ID Interval to
Maintenance
Disease Status at
Allotransplant
Disease Status at
Maintenance
Best
Response
Total
Cycles*
Cycle with Best
Response
Reason For
Discontinuation
Acute GVHD
Grade
Chronic
GVHD
14 82 CR CR CR 4 0 Progression Yes
16 90 VGPR SD SD 12 0 Yes
18 90 PR SD SD 1 0 GVHD II No
23 90 VGPR SD SD 1 0 GVHD III No
26 90 CR CR CR 1 0 GVHD II No
29 83 PR PR CR 7 2 Patient withdrew No
32 95 CR CR CR 12 0 No
33 90 CR CR CR 5 0 Neutropenia Yes
36 92 CR CR CR 1 0 GVHD IV No
38 91 PR SD CR 12 5 No
40 76 PR CR CR 12 0 No
44 170 VGPR CR CR 12 0 II Yes
47 125 PR SD PR 1 0 GVHD III No
49 131 PR PR SD 12 0 Yes
50 90 PR VGPR CR 12 3 No
52 68 VGPR SD CR 9 4 Infection II Yes
53 78 PR VGPR VGPR 1 0 Progression No
54 160 VGPR CR CR 11 0 Progression I No
62 69 PR PR PR 9 0 Progression I No
63 99 VGPR CR CR 1 0 Skin Rash I No
67 104 CR CR CR 12 0 No
70 96 CR CR CR 10 0 Progression Yes
72 171 CR CR CR 7 0 Progression No
73 97 VGPR CR CR 1 0 GVHD III No
78 108 SD PR VGPR 10 2 Progression No
81 147 VGPR CR CR 12 0 II No
83 118 VGPR SD VGPR 6 0 Neutropenia II No
85 135 sCR CR CR 12 0 No
86 105 VGPR SD VGPR 2 0 GVHD III No
87 115 PR SD PR 12 0 No
CR indicates complete response; GVHD, graft-versus-host-disease; PR, partial response; SD, stable disease; VGPR, very good partial response.
* Patients with ID 44, 49, 50, and 81 completed 12 months of maintenance before 12 cycles due to periods of therapy hiatus, all were less than 56 consecutive
days according to the protocol.
M. Alsina et al. / Biol Blood Marrow Transplant 20 (2014) 1183e11891186HLA-matched grafts. The most prevalent high-risk feature
was deletion of chromosome 13 in 43% (n ¼ 13) of the pa-
tients and this was associated with at least 1 additional high-
risk feature in all but 1 patient (n ¼ 12, 92%). Over 75% of
patients had a prior autoHCT. Sixty-three percent of patients
had received at least 2 prior lines of therapy. Thirteen pa-
tients had prior exposure to LEN.
Both related and unrelated donor transplantations were
included (40% and 60%, respectively) and peripheral blood
stem cells were used in 97% of patients. As per protocol, all
patients showed > 50% donor chimerism at the start of LEN
maintenance at 2 sequential assessments and 93% of patients
demonstrated > 90% donor chimerism. Twenty-seven pa-
tients had chimerism performed in peripheral blood samples
using variable number tandem repeats.Table 3
Non-GVHD Grade Three and Four Adverse Events
Adverse Event* Grade 3 Grade 4
Neutropenia 16 6
Thrombocytopenia 5 3
Skin rash 2 0
LFT abnormalities 0 1
Pain 3 0
Fever 1 0
Syncope 1 0
GVHD indicates graft-versus-host disease; LFT, liver function test.
* Number of reported infections (n ¼ 24): bacterial (n ¼ 14), viral (n ¼ 7),
fungal (n¼ 1), and unknown (n¼ 2). Sites: blood (n¼ 10), lower respiratory
tract (n ¼ 7), upper respiratory tract (n ¼ 5), stool (n ¼ 2).Treatment Compliance
All patients started LEN therapy at 10 mg/day at a median
of 96 days (range, 66 to 171) after alloHCT. Figure 1 shows the
patient ﬂow during the study and reasons for discontinua-
tion. Eleven patients (37%) were able to complete the plan-
ned 12 months of therapy and, of those, only 1 patient was
receiving the 25 mg/day dose. All other patients were at
doses of  10 mg/day. Eight patients discontinued therapy
during or immediately after the ﬁrst cycle.
Reasons for discontinuation of LEN were aGVHD (37%),
disease progression (37%), neutropenia (11%), patient with-
drawal (5%), infection (5%), skin rash (5%), and fever (5%)
(Table 2). The total number of cycles allowed in the studywas
360 (12 per patient). Of these, 59% of cycles were initiated
and 47% were completed. There was a much higher numberof cycles completed at a LEN dose of  10 mg/day (n ¼ 176)
than at doses >10 mg/day (n ¼ 33). The most common dose
administered was 10 mg/day (44%), even among patients
who tolerated LEN for more than 1 cycle (35%). Among the 11
patients who completed maintenance, the doses at the end
of maintenance were 5 mg every other day (n ¼ 5, 45%),
10mg/day (n¼ 3, 27%), 5 mg/day (n¼ 2,18%), and 25mg/day
(n ¼ 1, 9%).
Interruption of therapy was required in 30 cycles; the
most common reasons for holding LEN within a cycle were
neutropenia (57%), rash (13%), and GVHD (10%).
Treatment Safety
Grades 3 and 4 toxicities not related to GVHD occurring
during the study are summarized in Table 3. The most
common toxicities included neutropenia, thrombocytopenia,
and infections. There were 24 episodes of infections, most
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blood and respiratory tract. There were no neurologic, renal
toxicities, or thrombotic events.
Fourteen (47%) patients developed aGVHD after LEN.
Most common sites involved were the skin and gastroin-
testinal tract. As shown in Figure 2, the cumulative incidence
of grades II to IV and III to IV aGVHD 3 months after starting
LEN were 30% (95% conﬁdence interval [CI], 15% to 47%) and
17% (95% CI, 6% to 32%), respectively. Seven patients expe-
rienced chronic GVHD (cGVHD) during the study, ranging
from cycle 1 to 11, 2 patients had aGVHD before developing
cGVHD. None of the patients had to stop LEN after devel-
oping cGVHD. The cumulative incidence of TRM at
18 months from initiation of LEN was 11% (95% CI, 2% to 24%)
(Figure 3A).
Response
Disease status before the start of LENwas CR in 15 patients
(50%), very good partial response in 6 patients (20%), and
partial response in 9 patients (30%). Among 15 patients not in
CR before LEN: 4 achieved a CR,1 verygoodpartial response, 7
maintained stable disease, and 3 patients discontinued LEN
before disease assessment. There was an overall response
improvement of 33% after LEN maintenance.
Cumulative incidence of myeloma relapse or progression
at 18 months was 27% (95% CI, 13% to 44%) (Figure 3A).
Survival
The 18-month PFS and OS after initiation of maintenance
were 63% (95% CI, 43% to 77%) and 78% (95% CI, 58% to 90%),
respectively (Figure 3B). At last follow-up, there were 7
deaths; causes were disease progression (n ¼ 4), GVHD
(n ¼ 1), encephalopathy (n ¼ 1), and cardiopulmonary arrest
(n ¼ 1). Of these, 1 (3.3%) was deemed related to study drug
by the treating investigator. At last follow-up, there were no
secondary reported malignancies reported in this cohort.
DISCUSSION
In this multi-institutional clinical trial, we prospectively
examined the feasibility, tolerability, and safety of LEN
maintenance therapy after alloHCT in high-risk MM patients.
LEN was started at a median of 96 days (range, 66 to 171)
after alloHCT at a dose of 10 mg/day on days 1 to 21 in aFigure 2. Cumulative incidence of grade III to IV acute GVHD after initiation of LEN28-day cycle. There was intrapatient dose escalation by in-
crements of 5 mg to a maximum dose of 25 mg/day in the
same initial schedule, for up to 12 cycles. The planned
12 months of therapy was completed in 37% of patients, and
of these, 91%were at dose of 10mg/day. Themost common
reasons for discontinuation of LEN were aGHVD and disease
progression in 37% and 37% of subjects, respectively. The
most common reason to preclude dose escalation was mye-
losuppression. Our results indicate that although LEN can
induce GVHD and myelosuppression, it can still be tolerated
in some patients when given at low doses and with growth
factor support.
Recently, Kneppers et al. published results of a similar
study (HOVON 76 trial) [27]. In their study, they examined
the tolerability and efﬁcacy of LEN given at a ﬁxed dose of
10 mg/day for 24 months, starting 1 to 3 months after
alloHCT.
The authors concluded that LEN maintenance therapy
after alloHCT was not feasible, primarily because of the
development of GVHD; 46% of the patients needed to stop
therapy after 2 cycles, mainly because of the development of
GVHD. The main differences between the HOVON study and
ours are the patient population and the time to start LEN. The
HOVON study included patients with newly diagnosed MM
who received LEN maintenance after alloHCT treated as part
of their ﬁrst line of therapy, whereas in our study the patients
had received a mean of 1.76 prior lines of therapy, 77% had
received a prior autoHCT, and all were patients with high-
risk MM. In the HOVON study, LEN was started at a median
of 84 days after alloHCT (range, 28 to 189), but preferentially
within the ﬁrst 2 months of transplantation. Although
aGVHD was a common cause of discontinuation, 37% of
patients were also able to complete planned treatment, even
though at lower doses than projected. In both studies, the
1-year PFS and OS from the start of LENwere close to 70% and
90%, respectively. Given the high-riskMMpopulation treated
in our study, these results are encouraging.
LEN is a potent stimulator of T cell proliferation following
primary induction by T cell receptors. It is also known to
augment the production of IL-2, IL-10, and IFN-gamma and
exhibits dose-dependent inhibition of Il-1 and Il-6, as well as
modulation of IL-12 [28,29]. Because of the known immu-
nomodulatory effects of LEN and the implication of some ofmaintenance in recipients of allogeneic hematopoietic cell transplantation.
Figure 3. (A) Cumulative incidence of multiple myeloma progression or relapse, and transplant related mortality after initiation of LEN maintenance in recipients of
allogeneic hematopoietic cell transplantation. (B). Progression-free and overall survival after initiation of LEN maintenance in recipients of allogeneic hematopoietic
cell transplantation.
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tients with active GVHD. In our study, LEN did appear to
induce GVHD but it was manageable upon discontinuation of
the drug.
Given the positive effects on disease control (33% overall
response to LEN), the low TRM, and the manageable non-
GVHD toxicity, we conclude that LEN use can be consid-
ered, particularly in patients with high-risk MM. Patients can
be treated with low doses without escalation and they can be
monitored closely for development of GVHD. The survival
outcomes observed in this study suggest an important role
for maintenance therapy post alloHCT and it should be
further evaluated.
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